The news of EF Hutton reiterating a Buy rating on Adaptimmune Therapeutics and maintaining a $10 price target is positive for the company. This shows that the analyst has confidence in the company's potential and believes that the stock is undervalued. This could lead to increased investor interest and a potential short-term increase in the stock price.